sarteg 40 mg film - coated tablets
egis pharmaceuticals plc - Валсартан - 40 mg film - coated tablets
sarteg 80 mg film - coated tablets
egis pharmaceuticals plc - Валсартан - 80 mg film - coated tablets
sarteg 160 mg film - coated tablets
egis pharmaceuticals plc - Валсартан - 160 mg film - coated tablets
sarteg hct 160 mg/12,5 mg film - coated tablets
egis pharmaceuticals plc - валсартан и диуретици - 160 mg/12,5 mg film - coated tablets
sarteg hct 80 mg/12,5 mg film - coated tablets
egis pharmaceuticals plc - валсартан и диуретици - 80 mg/12,5 mg film - coated tablets
sarteg hct 160 mg/25 mg film - coated tablets
egis pharmaceuticals plc - валсартан и диуретици - 160 mg/25 mg film - coated tablets
daltex 50 mg/1000 mg film - coated tablets
50 mg/1000 mg film - coated tablets
daltex 50 mg/850 mg film - coated tablets
50 mg/850 mg film - coated tablets
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - Кистозна фиброза - Други продукти на дихателната система - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 и 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 и 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
orkambi
vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - Кистозна фиброза - Други продукти на дихателната система - Хапчета orkambi са показани за лечение на муковисцидоза (mv) при пациенти на възраст 6 и повече години, които са гомозиготами по мутации f508del в гена cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.